Loading...
•
Dec 31, 2019
Iovance Q4 2019 Earnings Report
Iovance reported fourth quarter and full-year 2019 financial results and provided a corporate update.
Key Takeaways
Iovance Biotherapeutics reported a net loss for the fourth quarter ended December 31, 2019, was $63.6 million, or $0.50 per share, compared to a net loss of $32.6 million, or $0.27 per share, for the fourth quarter ended December 31, 2018.
Advanced Iovance TIL and PBL products.
Conducted two planned pivotal programs for lifileucel in melanoma and LN-145 in cervical.
Initiated patient dosing in earlier lines of therapy and received clearance from FDA on a new IND to proceed to dose patients with our PBL product, IOV-2001.
Building internal manufacturing capability and expanding commercial team and infrastructure in anticipation for commercialization of Iovance TIL.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...